Close Up -- Samuel Thier

Volume 5, #13The Scientist June 24, 1991 Close Up Ask Samuel Thier why he wanted to become president of Brandeis University, and he'll point to the obvious reasons--among them the high quality of its faculty, the opportunity to lead a respected research university, and the chance to return to the Boston area, where he trained and taught. With academia under attack from many quarters, Thier says he relishes the chance to show the public that universities are still vital to the co

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Ask Samuel Thier why he wanted to become president of Brandeis University, and he'll point to the obvious reasons--among them the high quality of its faculty, the opportunity to lead a respected research university, and the chance to return to the Boston area, where he trained and taught. With academia under attack from many quarters, Thier says he relishes the chance to show the public that universities are still vital to the country's well-being.

Beyond that, however, something is driving the 53-year-old former medical school department chairman back to the campus. Despite his appointment last year to a second five-year term as president of the Institute of Medicine, Thier says he can't take future success for granted. And that means grabbing a very good opportunity when it appears rather than waiting for an even better one that might never come along.

"If I could control the outside world, I'd say ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies